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Many Gram-negative bacterial pathogens use a syringe-like
apparatus called a type III secretion system to inject virulence
factors into host cells. Some of these effectors are enzymes that
modify host proteins to subvert their normal functions.NleB is a
glycosyltransferase that modifies host proteins withN-acetyl-D-
glucosamine to inhibit antibacterial and inflammatory host
responses. NleB is conserved among the attaching/effacing
pathogens enterohemorrhagic Escherichia coli (EHEC), entero-
pathogenic E. coli (EPEC), and Citrobacter rodentium. More-
over, Salmonella enterica strains encode up to three NleB
orthologs named SseK1, SseK2, and SseK3. However, there are
conflicting reports regarding the activities and host protein tar-
gets among the NleB/SseK orthologs. Therefore, here we per-
formed in vitro glycosylation assays and cell culture experi-
ments to compare the activities and substrate specificities of
these effectors. SseK1, SseK3, EHEC NleB1, EPEC NleB1, and
C. rodentiumNleBblockedTNF-mediatedNF-Bpathway acti-
vation, whereas SseK2 and NleB2 did not. C. rodentium NleB,
EHEC NleB1, and SseK1 glycosylated host GAPDH. C. roden-
tium NleB, EHEC NleB1, EPEC NleB1, and SseK2 glycosylated
the FADD (Fas-associated death domain protein). SseK3 and
NleB2 were not active against either substrate. We also found
that EHEC NleB1 glycosylated two GAPDH arginine resi-
dues, Arg197 and Arg200, and that these two residues were
essential for GAPDH-mediated activation of TNF receptor-
associated factor 2 ubiquitination. These results provide
evidence that members of this highly conserved family of bac-
terial virulence effectors target different host protein sub-
strates and exhibit distinct cellular modes of action to sup-
press host responses.
The type three secretion system is a syringe-like apparatus
used by Gram-negative bacteria to deliver virulence proteins
(effectors) into infected host cells (1). Enteropathogenic Esche-
richia coli (EPEC)2 and enterohemorrhagic E. coli (EHEC)
inject effectors that target NF-B pathway components to
inhibit host anti-bacterial and inflammatory responses. NleC
cleaves the p50 and p65 NF-B subunits (2). NleD cleaves the
host JNK and p38MAPK (3). NleH1 prevents the nuclear trans-
location of the NF-B subunit RPS3 (4).
NleB was previously characterized as a glycosyltransferase
that catalyzes the transfer of GlcNAc to protein substrates
(5–7). NleB glycosylates arginine residues (6, 7). Several host
proteins such as the death domain-containing proteins
FADD, TRADD (tumor necrosis factor receptor type 1-associ-
ated death domain protein), and RIPK1 (receptor interac-
tion serine/threonine-protein kinase 1) are targets of NleB
N-GlcNAcylation activity (6). Glycosylation of TRADD Arg235
abrogates death domain interactions and the assembly of
TNFR1, leading to disrupted TNF signaling (6). EPEC NleB1
also antagonizes death domain signaling by GlcNAcylating
FADD Arg117 (7). GAPDH is a target of EHEC NleB1, and its
glycosylation inhibits GAPDH interaction with TRAF2, which
contributes to inhibiting NF-B pathway activation through an
unknown mechanism (5).
Salmonella enterica strains encode up to three NleB
orthologs named SseK1, SseK2, and SseK3 (8, 9). Conflicting
results of the roles of the SseK proteins in Salmonella virulence
have been presented. Deletion of sseK1, sseK2, or sseK3 was
reported not to be deleterious to Salmonella persistence (10).
Deletion of the sseK genes failed to impact Salmonella replica-
tion in RAW264.7 cells but resulted in attenuation in compet-
itive infection models (8). Another study reported that muta-
tion of sseK1 and/or ssek2 did not alter Salmonella virulence
during systemic infection of BALB/cmice (9). SseK1 and SseK2
additively inhibit TNF-inducedNF-Bactivation and cell death
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in macrophage infection experiments (11). SseK3 binds
TRIM32, an E3 ubiquitin ligase involved in TNF signaling and
interferon induction, although SseK3 does not GlcNAcylate
TRIM32 (12). The contribution of each SseK family member to
bacterial virulence remains to be clarified.
Another paradoxical result concerns EHEC and EPECNleB1
and their activities towardGAPDH.AlthoughEHECNleB1 gly-
cosylates GAPDH with GlcNAc (5), EPEC NleB1 does not (6),
despite 98.6% identity between the two proteins. The present
work was undertaken to compare the activities of the different
NleB/SseK orthologs and clarify their substrate specificity by
combining data from in vitro glycosylation assays andmamma-
lian cell culture assays. Mass spectrometry and site-directed
mutagenesis were used to demonstrate that EHEC NleB1
glycosylates GAPDH on Arg197 and Arg200. These residues
were essential for GAPDH-mediated activation of TRAF2
ubiquitination.
Results
Differential activities of NleB orthologs against NF-B
activation
NleB is a glycosyltransferase that glycosylates several host
proteins with GlcNAcs (5–7). EPEC NleB1 targets TRADD,
FADD, RIPK1, and TNFR1 to disrupt TNF signaling (6, 7).
EHEC NleB1 and Citrobacter rodentium NleB glycosylate
GAPDH to disrupt TRAF2 activation and downstream NF-B
signaling (5). To clarify potential functional differences among
the NleB effectors encoded by A/E pathogens, as well as the
three NleB orthologs in S. enterica (SseK1/2/3), we transfected
HEK293T cells with plasmids expressing each individual effec-
tor and then quantified both IB degradation and the nuclear
translocation of the NF-B p65 subunit after stimulating the
cells with TNF.
Both EHEC and EPEC NleB1, as well as C. rodentium NleB
and S. enterica SseK1 and SseK3, prevented IB degradation
and suppressed p65 nuclear translocation (Fig. 1A). Neither
NleB2 (the EHEC and EPEC proteins are identical), SseK2, nor
an enzymatically inactive form of EHEC NleB1 in which the
NleB1DADactive site ismutated (NleB1(AAA)) (5)were active
in this assay.
We also examined the extent to which TRAF2 polyubiquiti-
nation was inhibited and found that both EHEC and EPEC
NleB1, C. rodentium NleB, and SseK1 inhibited TRAF2 polyu-
biquitination to a greater extent as compared with the other
NleB orthologs (Fig. 1B). However, the extent of inhibition was
not as significant for EPEC NleB1, as compared with EHEC
NleB1, C. rodentium NleB, and SseK1 (Fig. 1B).
NleB orthologs differentially glycosylate GAPDH and FADD
We then sought to determine whether the NleB/SseK effec-
tors differ in their ability to glycosylate host substrates with
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Figure 1. NleB/SseK orthologs have differential activities toward host
NF-B signaling. A, analysis of IB degradation and NF-B p65 subunit
nuclear translocation. HEK 293T cells were transfected with the indicated
plasmids and treated 24h laterwith 50ng/ml TNF- for 30min. The cellswere
lysed and immunoblotted using the indicated antibodies. Tubulin and poly-
(ADP-ribose) polymerase (PARP)wereused tonormalize cytosolic andnuclear
protein concentrations, respectively. The asterisksused in quantification pan-
els indicate significantly different protein abundance as compared with the
TNF- control (n  3, ANOVA). B, analysis of TRAF2 polyubiquitination. HEK
293T cellswere transfectedwith the indicatedplasmids and treated 24 h later
with 50 ng/ml TNF- for 5 min. Cell lysates were immunoprecipitated (IP)
using FLAG antibody and immunoblotted for ubiquitin (Ub). Asterisks used in
quantification panels indicate significantly different TRAF2-Ub signal inten-
sity as comparedwith the TNF- control (n 3, ANOVA). C. rod, C. rodentium.
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GlcNAc. To do this, we incubated either GAPDH or FADD
with the NleB/SseK effectors and then monitored substrate
glycosylation using Western blotting. C. rodentium NleB and
EHEC NleB1 glycosylated both GAPDH and FADD (Fig. 2A).
By contrast, EPEC NleB1 and SseK2 only glycosylated FADD,
whereas SseK1 activity was limited to GAPDH. No activity was
observed for NleB2 or SseK3 toward either GAPDH or FADD.
We performed a semiquantitative analysis of these activities by
performing glycosylation experiments as a function of effector
concentration. Consistent with the qualitative analysis shown
in Fig. 2A, we observed that GAPDH and FADD were glycosy-
lated in an effector concentration-dependent manner. (Fig. 2,
B–D).
We also investigated the ability of each ortholog to bind their
respective GAPDH and FADD substrates. Only SseK2 and
SseK3 were unable to bind GAPDH (Fig. 2E). All effectors that
glycosylated FADD, except for SseK2, bound to FADD in the
GST pulldown (Fig. 2F). We were unable to detect a stable
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Figure 2. NleB/SseK orthologs differentially glycosylate GAPDH and FADD. A, in vitro GlcNAcylation assays. NleB/SseK enzymes (200 nM) were incubated
for 4 h at room temperature with either with GAPDH or FADD (1M) in 50 mM Tris-HCl, pH 7.4, 10 mM UDP-GlcNAc, 10 mM MnCl2, and 1mM DTT. The samples
were then subjected to Western blot detection using an anti-R-GlcNAc monoclonal antibody. B, titration of NleB/SseK orthologs in GAPDH and FADD
GlcNAcylation assays. Serial dilutions of NleB/SseK enzymes (6.25–200 nM) were incubated with either GAPDH or FADD (1M) and then subjected toWestern
blot detection using an anti-R-GlcNAc monoclonal antibody. C, quantification of GAPDH glycosylation. The data shown in B were quantified by normalizing
GlcNAc-GAPDH signals to total GAPDH signals. The data shown are representative of three independent experiments.D, quantification of FADDglycosylation.
The data shown in B were quantified by normalizing GlcNAc-FADD signals to total FADD signals. The data shown are representative of three independent
experiments. E and F, pulldown assays to detect binding between the NleB/SseK orthologs and GAPDH (E) or FADD (F). His-GAPDH or His-FADD were
individually incubated with each NleB/SseK ortholog then subjected to GST pulldown assays using glutathione-Sepharose beads (GE Healthcare). Protein
complexes were eluted with 10 mM reduced glutathione followed by SDS-PAGE analysis. GST was used as negative control. C. rod, C. rodentium.
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interaction between SseK2 and FADD, even though SseK2 gly-
cosylated FADD. SseK1 bound to FADD, despite being unable
to glycosylate it.
EHEC NleB1 GlcNAcylates GAPDH on Arg197 and Arg200
EPEC NleB1 glycosylates the arginine residues Arg117 of
FADD and Arg235 of TRADD (6, 7). To determine whether
EHEC NleB1 targets GAPDH arginines, we mutated all
GAPDH arginines to alanines (Fig. 3A, GAPDH R-free) and
incubated the recombinant mutant protein with EHEC GST-
NleB1 and UDP-GlcNAc. EHEC NleB1 glycosylated WT
GAPDH but did not glycosylate Arg-free GAPDH (Fig. 3A).
We subjected these protein samples to mass spectrometry
analysis and observed mass increments corresponding to one
and two single GlcNAc modifications on the LWRDGR-
GALQNIPASTGAAK peptide of GAPDH. These GlcNAc
modifications were mapped to Arg197 and Arg200 by using
MS/MS fragmentation (Fig. 3B). Neither the Arg-free GAPDH
nor R197A/R200A or R197K/R200K GAPDH mutants were
glycosylated, as measured by mass spectrometry or Western
blotting (Fig. 3,C–E).Mutating either Arg197 or Arg200 affected
the glycosylation of the other arginine, indicating a potential
cooperativity between the amino acids. The GAPDH mutants
still bound to EHEC NleB1, as determined using in vitro pull-
down assays (Fig. 3F).
GAPDHArg197 and Arg200 are required for GAPDH stimulation
of TRAF2 ubiquitination
We previously observed that GAPDH interacts with TRAF2
and that this interaction enhances TRAF2 ubiquitination (5).
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Figure 3. EHEC NleB1 glycosylates GAPDH on Arg197/Arg200. A, in vitro
GlcNAcylation of WT and GAPDH mutants by EHEC NleB1. The indicated
GAPDH proteins (1 M) were incubated for 4 h at room temperature with
EHEC NleB1 (200 nM) in 50 mM Tris-HCl, pH 7.4, 10 mM UDP-GlcNAc, 10 mM
MnCl2, and1mMDTT. Sampleswere then subjected toWesternblotdetection
using an anti-R-GlcNAcmonoclonal antibody. B, mass spectrometric analysis
of WT GAPDH tryptic digests. An Arg-GlcNAc modified peptide LWRDGR-
GALQNIIPASTGAAKwas identified onlywhenWTGAPDHwas incubatedwith
UDP-GlcNAc and NleB (right panels). The top right panel shows extracted ion
chromatograms for the GlcNAc-modified LWRDGRGALQNIIPASTGAAK pep-
tide (red trace, m/z  600.314) and for the unmodified LWRDGRGALQNI-
IPASTGAAK peptide (black trace, m/z 549.564). Unlabeled ion chromato-
gram peaks are not related to the LWRDGRGALQNIIPASTGAAK peptide. The
corresponding HCD-MS2 spectrum of the Arg-GlcNAc-modified LWRDGR-
GALQNIIPASTGAAK is shown in the bottom right panel. The blue square
denotes theGlcNAc residue. The top left panel shows extracted ion chromato-
grams for the GlcNAc-modified (red trace, m/z  800.103) and unmodified
(black trace,m/z 731.413) LWRDGRGALQNIIPASTGAAK peptides, demon-
strating that only the unmodified peptide is detectedwhenUDP-GlcNAc and
NleB are omitted. The corresponding HCD-MS2 spectrum of the unmodified
LWRDGRGALQNIIPASTGAAK peptide is shown on the bottom left. C, mass
spectrometric analysis of arginine-free (R free) GAPDH tryptic digests. The top
panels showextracted ion chromatograms for unmodified (black trace,m/z
1013.052) and GlcNAc-modified LWADGAGALQNIIPASTGAAK (red trace,
m/z 1114.582) peptides, demonstrating that only the unmodified peptide
is detected when GDP-GlcNAc and NleB are included (top right panel) or
excluded (top left panel) fromthe reaction. The correspondingHCD-MS2 spec-
tra for the unmodified LWADGAGALQNIIPASTGAAK peptides are shown in
the bottom panels. D, mass spectrometric analysis of the R197A/R200A
GAPDH tryptic digests. The top panels show extracted ion chromatograms
for unmodified (black trace, m/z  1013.052) and GlcNAc-modified
LWADGAGALQNIIPASTGAAK (red trace, m/z 1114.582) peptides, demon-
strating that only the unmodified peptide is detectedwhenGDP-GlcNAc and
NleB are included (top right panel) or excluded (top left panel) from
the reaction. The corresponding HCD-MS2 spectra for the unmodified
LWADGAGALQNIIPASTGAAK peptides are shown in the bottom panels. E, in
vitro GlcNAcylation of GAPDH alanine and lysine mutants. The indicated
GAPDH proteins (1 M) were incubated for 4 h at room temperature with
EHEC NleB1 (200 nM) in 50 mM Tris-HCl, pH 7.4, 10 mM UDP-GlcNAc, 10 mM
MnCl2, and 1 mM DTT. The samples were then subjected to Western blot
detection using an anti-R-GlcNAc monoclonal antibody. F, mutating GAPDH
Arg197/Arg200 does not affect NleB binding. Pulldown assays to detect bind-
ing between the GAPDHmutants and EHECNleB1. His-GAPDHmutants were
individually incubatedwith each EHECNleB1 and then subjected to GST pull-
down assays using glutathione-Sepharose beads (GE Healthcare). Protein
complexes were eluted with 10 mM reduced glutathione followed by SDS-
PAGE analysis. GST was used as negative control.
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To determine the functional importance of the GAPDHArg197
and Arg200 residues in the context of TRAF2 activity, we
mutated Arg197 and/or Arg200 to either alanine or lysine for use
in transfection experiments in a stableGAPDHknockdown cell
line (Fig. 4A). We transfected these cells with TRAF2-FLAG
and with different Myc-GAPDH mutants. By contrast to WT
GAPDH, the GAPDH mutants neither interacted with nor
stimulated TRAF2 polyubiquitination (Fig. 4B). Thus, GAPDH
Arg197 and Arg200 are essential both for the GAPDH-TRAF2
interaction and for activating TRAF2 polyubiquitination.
Although we had predicted that the GAPDH Arg197/Arg200
mutants would thus be resistant to EHEC NleB1-mediated
inhibition in these cell culture experiments, our finding that the
GAPDH mutants failed to interact with TRAF2 precluded us
from testing this hypothesis directly.
Discussion
Here we have unequivocally demonstrated that the NleB/
SseK orthologs have different acceptor substrate specificities
using both in vitro glycosylation assays and cell-based assays.
We found that EHECNleB1 andC. rodentiumNleB glycosylate
both GAPDH and FADD, whereas SseK1 only glycosylates
GAPDH, and SseK2 and EPEC NleB1 are only active with
FADD. Moreover, NleB2 and SseK3 were inactive with these
substrates (Fig. 2). The observed glycosylation activities among
the NleB/SseK effectors were not tightly linked to their sub-
strate binding, because EPEC NleB1 and NleB2 both bound to
GAPDH and SseK1 bound to FADD, despite having no appar-
ent ability to glycosylate these substrates.
Similarly, catalytically inactive mutants such as EPEC NleB1
(active site DAD mutated to AAA) still bind to FADD but do
not label it (13). By contrast, we failed to detect stable binding
between SseK2 and FADD in pulldown assays, even though
SseK2 glycosylated FADD in vitro. A similar resultwas obtained
in a previousmutagenesis study of EPECNleB1 inwhich several
EPECNleB1mutants glycosylated FADD yet exhibited weak or
no binding in pulldown assays (13). Thus, it is clear that cata-
lytic activity and substrate recognition and binding are distinct
aspects of the NleB/SseK effectors.
EHECNleB1 glycosylatedGAPDH,whereas EPECNleB1 did
not, even though the two proteins are almost identical (98%
identity) with only 7 amino acid differences (P35S, K42R,
S106N, Y111H, M193I, D302N, and C326S) among the 329
amino acid proteins. Unexpectedly, EPEC NleB1, similar to
EHECNleB1, showed binding affinity for GAPDHdespite lack-
ing catalytic activity with this substrate (Fig. 2E), providing evi-
dence that enzyme activity and substrate recognition are dis-
tinct aspects that appear not to be coupled in some particular
cases. Future site-directed mutagenesis studies may be inform-
ative in determining the NleB1 amino acids that govern and
dictate substrate specificity and catalysis.
NleB2 did not exhibit detectable glycosylation activity in our
assays. Nevertheless, NleB2 bound to GAPDH, but it did not
inhibit NF-B in transfection experiments. NleB2may glycosy-
late unknown targetswithGlcNAcor another sugar ormay lack
glycosylation activity. The role of NleB2 is currently unclear, as
is why both NleB1 and NleB2 are maintained in EPEC and
EHEC genomes.
We found that SseK3 has a similar phenotype as compared
with EHEC NleB1, EPEC NleB1, and SseK1 in our transfection
assays that examinedNF-Bpathway inhibition (Fig. 1), despite
our in vitro assays lacking activity toward FADD or GAPDH
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Figure 4. Function of GAPDH arginines 197 and 200 in TRAF2 polyubiq-
uitination. A, GAPDH knock down efficiency. HEK293T cells were transfected
with the shRNA plasmid psi-LVRU6GP targeting the GAPDH 3-UTR mRNA.
Stable cell lineswere created using puromycin selection. Tubulinwas used to
normalize GAPDH abundance. Asterisks indicate protein abundance signifi-
cantly different from that of the control (n  3, ANOVA). B, GAPDH R197/
Arg200mutants neither interactwith nor activate TRAF2polyubiquitination in
HEK293T cells. GAPDH stable cell line was co-transfected with FLAG-TRAF2,
HA-ubiquitin together with either Myc-GAPDH WT or the indicated GAPDH
mutants. After 48 h, cell lysates were immunoprecipitated (IP) with anti-FLAG
antibody, followed by immunoblotting with anti-ubiquitin or anti-Myc anti-
body. The abundance of endogenous GAPDH and transfected forms of
GADPH-Myc is also shown. Asterisks used in quantification panels indicate
significantly different TRAF2-Ub signal intensity as compared with the TNF-
control (n 3, ANOVA). Endo., endogenous; Exo., exogenous; Ub, ubiquitin.
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(Fig. 2). SseK3 binds but does not glycosylate TRIM32, and this
interaction is required for inhibiting NF-B (12), suggesting
that SseK3may not be a highly active enzyme. SseK1 and SseK3
have additive effects on inhibiting NF-B, whereas SseK2 has a
moderate impact on this pathway (11). Our in vitro data show
that SseK2 glycosylates FADD, whereas data from transfection
experiments (11) indicate that SseK1, rather than SseK2, glyco-
sylates FADD. It is conceivable that effector activitiesmay differ
between in vitro glycosylation assays from their in vivo context
as studied in transfection experiments.
NleB2 and SseK3 both contain the conserved DXD motif
found in glycosyltransferases, suggesting that theymay be enzy-
matically active, although host substrates for these proteins
have not been identified. Additional glycosyltransferase motifs
are also found in these two orthologs. NleB2 is 62% identical to
EHEC NleB1, whereas SseK3 is 60% identical to SseK1. The
absence of their detectable activities toward GAPDH and
FADD in vitro does not exclude their potential activities against
other substrates that may affect host NF-B pathway activity.
NleB2 and SseK3 might also require different in vitro condi-
tions for optimal enzyme activity.
We showed that EHEC NleB1 glycosylates GAPDH with
GlcNAc on two different arginines, Arg197 and Arg200 (Fig. 3),
in contrast to the single arginine residue GlcNAcylated in
FADD or TRADD (6, 7). Glycosylation of both residues are
critical for GAPDH-mediated activation of TRAF2 ubiquitina-
tion (Fig. 4B). Our data also suggest that the two Arg197 and
Arg200 residues may be essential to maintain the complex in a
proper conformation that may be necessary to recruit other
proteins to the TRAF2 complex.
The amino acid region surrounding the GAPDH arginine
residue targeted by EHEC NleB1 is partly conserved within the
other EPEC NleB1 targets TRADD and FADD (WRDGRGAL
for GAPDH, WRKVGRSL for TRADD, and WRRLARQL for
FADD) (6, 7), suggesting some commonalities among the rec-
ognition sequences. The identification of additional NleB tar-
gets, together with site-directed mutagenesis and structural
studies, may be helpful in establishing a consensus NleB recog-
nition motif. In summary, we present compelling evidence for
distinct substrate specificities of virulence effector enzymes
and further demonstrate that substrate binding and catalytic
activity of these effectors may be distinct.
Experimental procedures
Cloning
The primers used in this study are listed in Table 1. The
plasmids used in this study are listed in Table 2.
Protein purification
E. coli BL21 (DE3) was transformed with pET42a-nleB,
pET42a-traf2, pET28a-gapdh, or pET15b-fadd and grown in
LB to an A600 of 0.4. Isopropyl -D-thiogalactopyranoside (0.5
mM) was added for 4 h, bacteria were pelleted using centrifuga-
tion, and the pellet was suspended in 50mM sodium phosphate,
pH 8.0, 0.5mg/ml lysozyme). The suspension was incubated on
ice for 30 min with occasional shaking. An equal volume of 50
mM sodium phosphate, pH 8.0, 2 M NaCl, 8 mM imidazole, 20%
glycerol, 1% Triton X-100 was added, and after 30 min on ice,
the bacterial lysate was sonicated and then clarified by centrif-
ugation. The supernatant was incubated with nickel-nitrilotri-
acetic acid beads (Qiagen) with gentle rotation for 2 h at 4 °C,
then loaded on a Poly-Prep Chromatography Column (Bio-
Rad), and washed with 5 bead volumes of 50 mM sodium phos-
phate, pH 8.0, 600 mM NaCl, 10% glycerol, 60 mM imidazole.
Proteins were eluted in 50 mM sodium phosphate, pH 8.0, 600
mM NaCl, 10% glycerol, 250 mM imidazole.
GlcNAcylation assays
NleB/SseK effector proteins (200 nM) were incubated with
either GAPDH or FADD (1 M) for 4 h at room temperature in
50 mM Tris, pH 7.4, 10 mM MnCl2, 1 mM UDP-GlcNAc, 1 mM
DTT. The reactions were terminated by adding 250 mM Tris-
HCl, pH 6.8, 10% sodium dodecyl sulfate, 30% glycerol, 5%
-mercaptoethanol, 0.02% bromphenol blue and then immu-
noblotted using an anti-R-GlcNAc monoclonal antibody
(Abcam).
Pulldown assays
Pulldown experiments were performed as described (14).
GST-tagged proteins (10 M) were immobilized on glutathi-
one-Sepharose beads (GE Healthcare) and then mixed with
His-tagged prey proteins (10 M) in 20 mM Tris-HCl, pH 7.9,
20% glycerol, 1 mM EDTA, 5 mM MgCl2, 0.1% Nonidet P-40, 1
mMDTT, 0.2mMPMSF, 100mMNaCl, supplementedwith 0.33
unit/l of RNase A and DNase I. After overnight incubation
at 4 °C, the beads were washed four times with 20 mM Tris-
HCl, pH 7.9, 20% glycerol, 1 mM EDTA, 5 mM MgCl2, 0.1%
Nonidet P-40, 1 mM DTT, 0.2 mM PMSF, 1 M NaCl. Proteins
were eluted with 10 mM reduced glutathione and analyzed
using SDS-PAGE.
Mass spectrometry
Proteins (10 g) were precipitated and washed in 90% ice-
cold acetone, air-dried briefly, and then resolubilized in 50 mM
ammonium bicarbonate containing 0.1% Rapigest (Waters).
The sampleswere reduced in 5mMDTTat 56 °C for 30min and
subsequently alkylated at room temperature for 30 min by the
addition of 10 mM iodoacetamide. Each sample was digested
overnight with 0.1 g of LysC protease (Roche) at 37 °C. Pep-
tides were purified and concentrated using reversed-phased
C18 chromatography with in-house packed Stagetips (Empore
disk-C18, 3M).
LysC digests were separately analyzed using a setup com-
posed of an EASY-nLC 1000UHPLC (Thermo Scientific) inter-
faced via a nanoSpray Flex ion source to an LTQ-Orbitrap
Velos Pro hybrid mass spectrometer. The EASY-nLC 1000 was
operated using a single analytical column setup (PicoFrit Emit-
ters, New Objectives, 75-m inner diameter) packed in-house
withReprosil-Pure-AQC18phase (Dr.Maisch, 1.9-mparticle
size). Peptideswere separated using a 90-min LC gradient oper-
ated at 200 nl/min. The mass spectrometer was operated in
data-dependent mode. MS1 precursor ion acquisition was per-
formed in theOrbitrap (nominal resolution of 30,000), followed
by HCD and electron-transfer dissociation (ETD) fragmenta-
tions of the top five multiply charged ions. MS2 scans were
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acquired in the Orbitrap mass analyzer using a resolution set-
ting of 15,000.
Data processing and analysis were performed using Pro-
teomeDiscoverer 1.4 (Thermo Fisher Scientific). Enzyme spec-
ificity was set to LysC allowing for onemissed cleavage site. Full
specificity and semispecific cleavages were considered. Peptide
mass tolerance was 10 ppm; fragment ion mass tolerance was
0.05 atomicmass unit; carbamidomethylwas set as a fixedmod-
ification for cysteine residues. Methionine oxidation and Hex-
NAc modification of arginine were used as variable modifica-
tions. The data were filtered for only high confidence (p 0.01)
identifications. Peptide identifications with HexNAcmodifica-
tions were inspected manually to verify the accuracy of the
assignments.
Cell fractionation
Cytosolic and nuclear protein extracts were prepared from
HEK293T cells using the NE-PER nuclear and cytoplasmic
extraction reagents (Thermo). TNF- stimulation (30 min, 50
ng/ml) was used to monitor IB degradation and phosphory-
lated p65 nuclear translocation. Poly(ADP-ribose) polymerase
and -tubulin were used to normalize the protein concentra-
tions of nuclear and cytoplasmic fractions, respectively.
Ubiquitination assays
HEK293T cells were transfected and treated with TNF- (50
ng/ml, 5 min). The cells were washed with cold PBS, and cell
pellets were lysed in 50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1
mM EDTA, 1% Triton X-100 on ice for 30 min and then mixed
with anti-FLAGM2 affinity resin and rotated at 4 °C overnight.
The resinswere centrifuged at 8,000 g for 30 s at 4 °C and then
washed three times with cold TBS. The resins were resus-
pended in SDS sample loading buffer, boiled for 10 min, and
immunoblotted with appropriate antibodies.
GAPDH stable cell line construction
shRNAs targeting the GAPDH 3-UTR mRNA were synthe-
sized and cloned into the psi-LVRU6GP shRNA mammalian
expression vector (GeneCopoeia). CSHCTR001-LVRU6GP
(GeneCopoeia) was used as a scrambled sequence control. HEK
Table 1
Primers used in this study
Description Sequence
C. rodentium nleB BamHI forward G4ATC2ATGT2ATCTC2AT2A3TGT2C
C. rodentium nleB XhoI reverse C3TCGAGC2ATGA2CTGT2G2TATAC
C. rodentium nleB NleB forward ATATCTAGAGC2AC2ATGTAC3ATACGACGTC3G2ACTACGCGT2ATCTC2AT2A3T
C. rodentium nleB NleB reverse ATATGCG2C2GCT2AC2ATGA2CTGT2G2TATACAT
EHEC nleB1 NcoI forward ATCGCATATGC3ATG2CAT2ATCT2CAT2A3TGTC2T2CA2T
EHEC nleB1 SalI reverse ATCG2TCGAC3ATGA2CTGCAG2TATACATACTG2T
EHEC nleB2 XbaI forward ATATCTAGAGC2AC2ATGTAC3ATACGACGTC3G2ACTACGCGC3ATG2CACT3CA
EHEC nleB2 NotI reverse ATATGCG2C2GCT2AC2ATGA2CTGCATGTATACTGACT2
EHEC nleB2 BamHI forward CGCG3ATC2ATGCT3CAC2GATA2G2ACA2CT3C
EHEC nleB2 XhoI reverse CGCGCTCGAGC2ATGA2CTGCATGTATACTGACT
EHEC nleB1 XbaI forward ATATCTAGAGC2AC2ATGTAC3ATACGACGTC3G2ACTACGCGT2ATCT2CAT2A3T
EHEC nleB1 NotI reverse ATATGCG2C2GCT2AC2ATGA2CTGCAG2TATACATACTG2T
EPEC nleB1 NcoI forward ATCGCATATGC3ATG2CAT2ATCT2CAT2A3TGTC2T2CA2T
EPEC nleB1 SalI reverse ATCG2TCGAC3ATGA2CTGCTG2TATACATACT
EPEC nleB1 NotI reverse ATATGCG2C2GCT2AC2ATGA2CTGCTG2TATACATACT
FADD NdeI forward CG2A2T2CTATATG3TGA2GA2GATCTGTGCGC2
FADD BamHI reverse CG2A2T2CG2ATC2TCA2GCGC2GCTACGAT4GCAG
GAPDH BamHI forward G4ATC2ATG4A2G2TG
GAPDH XhoI reverse C3TCGAGCTC2T2G2AG2
GAPDH R200A forward G2A3CTGTG2CGTGATG2CGC2G4CTCTC2
GAPDH R200A reverse G2AGAGC3G2CGC2ATCACGC2ACAGT3C2
GAPDH R197A forward G2A3CTGTG3CTGATG2C2GCG3CTCTC2AGA2CATCATC2
GAPDH R197A reverse G2ATGATGT2CTG2AGAGC4GCG2C2ATCAGC3ACAGT3C2
GAPDH R197A,R200A forward G3A3CTGTG3CTGATG2CGCTG4CT
GAPDH R197A,R200A reverse AGC4AGCGC2ATCAGC3ACAGT3C3
GAPDH R197K forward G2ATG2C4TC2G3A3CTGTG2A2G2ATG2C2GCG4CTCT
GAPDH R197K reverse AGAGC4GCG2C2ATC2T2C2ACAGT3C3G2AG4C2ATC2
GAPDH R200K forward G2ATG2C4TC2G3A3CTGTG2CGTGATG2CA2G5CTCTC2AGA2CATC
GAPDH R200K reverse GATGT2CTG2AGAGC4CT2GC2ATCACGC2ACAGT3C3G2AG4C2ATC2
GAPDH R197K,R200K forward G2ATG2C3TC2G3A2CTGTG2A2G2ATG2CA2G5CTCTC2AGA2CATC
GAPDH R197K,R200K reverse GATGT2CTG2AGAGC4CT2GC2ATC2T2C2ACAGT3C3G2AG4C2ATC2
GAPDH R197A,R200A forward G3A3CTGTG3CTGATG2CGCTG4CT
GAPDH R197A,R200A reverse AGC4AGCGC2ATCAGC3ACAGT3C3
GAPDH shRNA UTR-1 forward GATC2G2AGC2GCAC2T2GTCATGTACTCA2GAG2TACATGACA2G2TGCG2CTCT6G2
GAPDH shRNA UTR-1 reverse A2T2C2A6GAGC2GCAC2T2GTCATGTAC2TCT2GAGTACATGACA2G2TGCG2CTC2G
Salmonella sseK1 XbaI forward ATATCTAGAGC2AC2ATGTAC3ATACGACGTC3G2ACTACGCGATC3AC2AT2A3T
Salmonella sseK1 NotI reverse ATATGCG2C2GC2TACTGCACATGC2TCGC3ATGA2CT
Salmonella sseK2 XbaI forward ATATCTAGAGC2AC2ATGTAC3ATACGACGTC3G2ACTACGCG2CACGT4A2TGC2
Salmonella sseK2 NotI reverse ATATGCG2C2GCT2AC2TC2A2GA2CTG2CAGT2A3CT
Salmonella sseK3 XbaI forward ATATCTAGAGC2AC2ATGTAC3ATACGACGTC3G2ACTACGCGT4CTCGAGTCAGA
Salmonella sseK3 NotI reverse ATATGCG2C2GCT2ATCTC2AG2AGCTGATAGTCA3
Salmonella sseK1 BamH1 forward CGCG3ATC2ATGATC3AC2AT2A3TAGATATGT2C
Salmonella sseK1 XhoI reverse CGCGCTCGAGCTGCACATGC2TCGC3ATGA2
Salmonella sseK2 BamHI forward CGCG3ATC2ATG2CACGT4A2TGC2GCT4A
Salmonella sseK2 XhoI reverse CGCGCTCGAGC2TC2A2GA2CTG2CAGT2A3CT
Salmonella sseK3 NcoI forward CGCGC2ATG2T3CTCGAGTCAGAG2T4CT3C
Salmonella sseK3 SalI reverse CGCG2TCGACATC2TCTC2AG2AGCTGATAGTC
TRAF2 BamHI forward GCG2ATC2ATG2CTGCAGCTAGCGTGAC2
TRAF2 HindIII reverse GCA2GCT2G2AGC3TGTCAG2TC2ACA2TG2
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293T cells were seeded onto 100-mm dishes 24 h before trans-
fection and then transfectedwith 5g of plasmids using PolyJet
transfection reagent (SignaGen Laboratories). After 48 h of incu-
bation at 37 °C, the cells were passaged in medium containing
puromycin (2 g/ml; InvivoGen) for selection. Puromycin-resist-
ant colonies were isolated by serial dilution in 96-well plates, after
which individual clones were expanded in selectionmedium.
Statistical analyses
Protein abundance was quantified using Li-COR Image Stu-
dio software. IB degradation, p65 nuclear translocation, and
TRAF2 polyubiquitination were analyzed statistically using
one-way analysis of variance (ANOVA). p values  0.05 were
considered significant.
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Table 2
Plasmids used in this study
Description Source
HA-C. rodentium_NleB This study
HA-EHEC_NleB1 Ref. 5
HA-EHEC_NleB1(AAA) Ref. 5
HA-EPEC_NleB1 This study
HA-NleB2 This study
HA-SseK1 This study
HA-SseK2 This study
HA-SseK3 This study
GST-C. rodentium_NleB This study
GST-EHEC_NleB1 This study
GST-EPEC_NleB1 This study
GST-NleB2 This study
GST-SseK1 This study
GST-SseK2 This study
GST-SseK3 This study
His-GAPDH Ref. 5
His-GAPDH (R197A) This study
His-GAPDH (R200A) This study
His-GAPDH (R197A,R200A) This study
His-GAPDH (R197K) This study
His-GAPDH (R200K) This study
His-GAPDH (R197K,R200K) This study
GAPDH shRNA in psi-LVRU6GP This study
CSHCTR001-LVRU6GP, scrambled shRNA control GeneCopoeia
Myc-GAPDH Ref. 15
Myc-GAPDH (R197A) This study
Myc-GAPDH (R200A) This study
Myc-GAPDH (R197A,R200A) This study
Myc-GAPDH (R197K) This study
Myc-GAPDH (R200K) This study
Myc-GAPDH (R197K,R200K) This study
Ubiquitin-HA Ref. 16
FLAG-TRAF2 Ref. 5
GST-TRAF2 This study
His-FADD This study
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